News

Neurologist Recommends MS Approach Based on Alternative Medicine

Unconventional medical approaches and lifestyle changes may help patients suffering from multiple sclerosis (MS) improve their health and well-being, according to Allen Bowling, MD, PhD, an internationally recognized neurologist and specialist in alternative medicine. The physician has designed a seven-step method based on his expertise, which is presented on his…

Genzyme’s Lemtrada Approved by the FDA

Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…

Sailboat Crewed by MS Patients Circumnavigating the Globe

Oceans of Hope, a 67-foot sail yacht currently docked at North Cove Marina, New York, is on a round-the-world voyage to become the first ship to ever circumnavigate with a crew of people who have Multiple Sclerosis. The voyage, initiated by Sailing Sclerosis Foundation, set sail from Copenhagen, Denmark…

Obesity Linked To Multiple Sclerosis?

A team of researchers at the Tel Aviv University report the role of obesity as a major risk factor triggering and maintaining autoimmune diseases, such as Crohn’s Disease and multiple sclerosis. The study was published in Autoimmunity Reviews. In autoimmune diseases, the immune system reacts against the body…

Teva and Active Biotech Expand Investigational MS Treatment Program

Drug manufacturers Teva Pharmaceutical Industries Ltd. and Active Biotech announced that they expanding the ongoing clinical research program for the study of laquinimod, a potential treatment for primary progressive multiple sclerosis (PPMS), as the companies are now initiating the ARPEGGIO trial. In addition, Teva has also announced the screening…

Genzyme Clinical Trial for Relapsing-Remitting MS Enrolls 1st Patient

Sanofi subsidiary and rare disease treatment specialist Genzyme has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug for relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically…

Neuroprotective Qualities of Masitinib Drug in Stroke Encouraging For MS Indication

An encouraging experimental drug that is being developed for Multiple Sclerosis continues to show promise in being able to offer neuroprotective benefits — an effect that could slow and eventually cure MS. Masitinib, which is being developed by AB Science for numerous neurological indications, including Alzheimer’s disease, progressive multiple sclerosis, and amyotrophic…

Opexa Joins National Multiple Sclerosis Society to Sponsor Walk MS

The National Multiple Sclerosis Society‘s Lone Star Chapter, which is sponsoring the nonprofit organization’s annual Houston-area Walk MS fundraisers, has announced that Woodlands-based biopharmaceutical company Opexa Therapeutics, a company currently developing personalized immunotherapies for multiple sclerosis (MS), will also support the fundraising effort. This is the fourth consecutive year that…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here